Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 269-274

  Parikh, Sameer A ^a   Kantarjian, Hagop M ^a   Richie, Mary Ann ^a   Cortes, Jorge E ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

D816V mutation; KIT mutation; Mast cell disease; MTOR

Indexed keywords

CLADRIBINE; DACLIZUMAB; DASATINIB; EVEROLIMUS; IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; DIARRHEA; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUCOSITIS; MUTATION; NEUTROPENIA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; SIROLIMUS; TREATMENT OUTCOME;

EID: 76349119028     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903486220     Document Type: Article

References (24)

1. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007;74:121-132.
2. Boissan M, Feger F, Guillosson JJ, Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 2000;67:135-148.
3. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002;127:110-114.
4. Gabillot-Carre M, Lepelletier Y, Humbert M, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006;108:1065-1072.
5. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120: 747-759.
6. O'Reilly T, Vaxelaire J, Muller M, et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43:71 (Abstract 359).
7. Lane H, Schnell C, Theuer A, et al. Antiangiogenic activity of RAD001, an orally active anticancer agent. Proc Am Assoc Cancer Res 2002;43:184 (Abstract 922).
8. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;10:1674-1681.
9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
10. Rao RD, Allred JB, Windschitl HE, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2007;25:8530.
11. Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced non smallcell lung cancer. Cancer 2007;110:599-605.
12. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
13. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-5736.
14. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006;107:345-351.
15. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-536.
16. Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther 2007;7:1597-1611.
17. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-1484.
18. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinibresistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108: 286-291.
19. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 2008;80: 456-458.
20. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-3915.
21. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005;106: 2865-2870.
22. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-1595.
23. Tabernero J, Rojo F, Calvo E, et al. Dose-and scheduledependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-1610.
24. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26: 1596-1602